We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
-3.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.3B
AUM Growth
-$140M
(-5.7%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
4.61%
Top 10 Holdings %
Top 10 Hldgs %
42.59%
Holding
80
New
11
Increased
12
Reduced
36
Closed
4
Top Buys
| 1 |
CTLT
CATALENT, INC.
CTLT
|
+$37.7M |
| 2 |
DexCom
DXCM
|
+$37.6M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$34.7M |
| 4 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$33.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$31.7M |
Top Sells
| 1 |
ONEM
1Life Healthcare
ONEM
|
+$38.9M |
| 2 |
Xenon Pharmaceuticals
XENE
|
+$38.2M |
| 3 |
Pliant Therapeutics
PLRX
|
+$27.1M |
| 4 |
AKRO
Akero Therapeutics
AKRO
|
+$26.2M |
| 5 |
Replimune Group
REPL
|
+$24.2M |
Sector Composition
| 1 | Healthcare | 98.78% |
| 2 | Industrials | 1.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Bristol-Myers Squibb
BMY
$120B
| $31.2M | 1.35% |
+449,442
| New | +$31.7M |
|
27
Regenxbio
RGNX
$631M
| $31M | 1.35% |
1,640,725
-272,787
| -14% | -$6.04M |
|
|
IMGN
28
DELISTED
Immunogen Inc
IMGN
| $30.9M | 1.34% |
8,046,217
-486,600
| -6% | -$2.07M |
|
29
Elevance Health
ELV
$84.2B
| $30.5M | 1.32% |
66,398
+27,428
| +70% | +$13.1M |
|
|
VTYX
30
DELISTED
Ventyx Biosciences
VTYX
| $27.3M | 1.19% |
815,774
-79,200
| -9% | -$3.08M |
|
31
Entrada Therapeutics
TRDA
$272M
| $26.6M | 1.15% |
1,831,608
-22,500
| -1% | -$300K |
|
32
ADC Therapeutics
ADCT
$162M
| $26.5M | 1.15% |
13,565,249
+5,974,400
| +79% | +$22M |
|
33
Humana
HUM
$48.8B
| $25.3M | 1.1% |
+52,079
| New | +$25.7M |
|
|
AUGX
34
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $25M | 1.09% |
14,380,327
| – | – |
|
35
Scholar Rock
SRRK
$6.44B
| $25M | 1.08% |
3,124,226
+1,028,406
| +49% | +$10.4M |
|
|
RPTX
36
DELISTED
Repare Therapeutics
RPTX
| $24.9M | 1.08% |
2,533,050
-151,346
| -6% | -$1.74M |
|
37
Prime Medicine
PRME
$625M
| $24.5M | 1.06% |
1,992,843
-216,507
| -10% | -$3.53M |
|
38
Nurix Therapeutics
NRIX
$2.47B
| $24.4M | 1.06% |
2,749,384
-251,400
| -8% | -$2.62M |
|
39
Stevanato
STVN
$5.35B
| $23.4M | 1.01% |
901,932
-40,593
| -4% | -$871K |
|
40
Charles River Laboratories
CRL
$11B
| $23.3M | 1.01% |
+115,328
| New | +$26.1M |
|
41
Immunovant
IMVT
$8.14B
| $20.4M | 0.89% |
1,317,031
+228,900
| +21% | +$3.97M |
|
|
GRTS
42
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $19.3M | 0.84% |
6,926,926
-4,534
| -0.1% | -$13K |
|
43
Centene
CNC
$33B
| $17.5M | 0.76% |
277,351
-3,909
| -1% | -$278K |
|
44
Shattuck Labs
STTK
$626M
| $16.5M | 0.72% |
5,619,914
| – | – |
|
45
Atara Biotherapeutics
ATRA
$76.9M
| $16.3M | 0.71% |
224,482
-25,228
| -10% | -$2.45M |
|
|
VERV
46
DELISTED
Verve Therapeutics
VERV
| $16.2M | 0.7% |
1,120,679
-101,224
| -8% | -$1.98M |
|
47
IQVIA
IQV
$34.8B
| $14.3M | 0.62% |
+71,657
| New | +$15.3M |
|
48
Absci
ABSI
$1.66B
| $14.1M | 0.61% |
8,031,094
| – | – |
|
|
ETNB
49
DELISTED
89bio
ETNB
| $13.7M | 0.59% |
+900,000
| New | +$11.7M |
|
50
Annexon
ANNX
$1.02B
| $13.5M | 0.59% |
3,503,190
| – | – |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO